Phase 1B Study of RiVax, a Vaccine to Prevent the Toxic Effects of Ricin

NCT00812071 ↗

Phase 1 Completed 30 enrolled University of Texas Southwestern Medical Center

Non-randomizedSingle-groupOpen-labelPrevention

Summary

Dose escalation study: 3 dose groups. 5 patients in each dose group, then 15 more patients in "best" group. 3 vaccinations in volunteers, at 0 6 and 16 weeks.

Timeline

Start: 2008-03
Primary completion: 2012-01
Completion: 2012-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RiVax	Vaccine	—	—

Indications

No indication recorded.